Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines

Advanced hepatocarcinoma (HCC) is an aggressive malignancy with poor prognosis and limited treatment options. Alterations of the cyclin D-CDK4/6-Rb pathway occur frequently in HCC, providing the rationale for its targeting at least in a molecular subset of HCC. In a panel of HCC cell lines, we inves...

Full description

Bibliographic Details
Main Authors: Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara A. Bonelli, Daniele Cretella, Roberta Alfieri, Andrea Cavazzoni, Maricla Galetti, Patrizia Bertolini, Gabriele Missale, Pier Giorgio Petronini
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
hepatocarcinoma (HCC)
CDK4/6 inhibition
palbociclib (PD-0332991)
regorafenib
metabolism
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.563249/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.563249/full

Similar Items